Rheumatoid Arthritis Clinical Studies

You have full text access to this OnlineOpen article

The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: A cohort and nested case–control analysis†

  1. Frederick Wolfe1,*,
  2. Kaleb Michaud2

Article first published online: 29 AUG 2008

DOI: 10.1002/art.23811

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 58, Issue 9, pages 2612–2621, September 2008

Additional Information

How to Cite

Wolfe, F. and Michaud, K. (2008), The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: A cohort and nested case–control analysis. Arthritis & Rheumatism, 58: 2612–2621. doi: 10.1002/art.23811

Author Information

  1. 1

    National Data Bank for Rheumatic Diseases, Wichita, Kansas, and University of Kansas School of Medicine, Wichita

  2. 2

    University of Nebraska Medical Center, Omaha, and National Data Bank for Rheumatic Diseases, Wichita, Kansas

*National Data Bank for Rheumatic Diseases, 1035 North Emporia, Suite 288, Wichita, KS 67214

  1. †

    The National Data Bank for Rheumatic Diseases has conducted safety registries for Centocor, Sanofi-Aventis, and Bristol-Myers Squibb, and has received research grants from Abbott, Amgen, Wyeth-Australia, Merck, and Pfizer.

Publication History

  1. Issue published online: 29 AUG 2008
  2. Article first published online: 29 AUG 2008
  3. Manuscript Accepted: 29 MAY 2008
  4. Manuscript Received: 27 AUG 2007

Funded by

  • Abbott
  • Amgen
  • Wyeth-Australia
  • Merck
  • Pfizer

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (101K)

REFERENCES

  • 1
    Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303–7.
  • 2
    Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1608–12.
  • 3
    Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 2004; 63: 952–5.
  • 4
    Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 2004; 93: 198–200.
  • 5
    Kitas GD, Erb N. Tackling ischaemic heart disease in rheumatoid arthritis [review]. Rheumatology (Oxford) 2003; 42: 607–13.
  • 6
    Del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737–45.
    Direct Link:
  • 7
    Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004; 50: 3444–9.
    Direct Link:
  • 8
    Maxwell SR, Moots RJ, Kendall MJ. Corticosteroids: do they damage the cardiovascular system? [review]. Postgrad Med J 1994; 70: 863–70.
  • 9
    Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system [review]. Can J Cardiol 2000; 16: 505–11.
  • 10
    McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD: a critical review [review]. Chest 1997; 111: 732–43.
  • 11
    Hansson GK. Inflammation, atherosclerosis, and coronary artery disease [review]. N Engl J Med 2005; 352: 1685–95.
  • 12
    Curb JD, Abbott RD, Rodriguez BL, Sakkinen P, Popper JS, Yano K, et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation 2003; 107: 2016–20.
  • 13
    Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557–65.
  • 14
    Hallenbeck JM. Inflammatory reactions at the blood-endothelial interface in acute stroke [review]. Adv Neurol 1996; 71: 281–97.
  • 15
    Wolfe F, Michaud K. The effect of methotrexate and anti–tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007; 56: 1433–9.
    Direct Link:
  • 16
    Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti–tumor necrosis factor therapy. Arthritis Rheum 2006; 54: 628–34.
    Direct Link:
  • 17
    Michaud K, Wolfe F. The development of a rheumatic disease research comorbidity index for use in outpatients with RA, OA, SLE and fibromyalgia (FMS) [abstract]. Arthritis Rheum 2007; 56 Suppl 9: S596–7.
  • 18
    Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137–45.
    Direct Link:
  • 19
    Wolfe F. A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis Rheum 2000; 43: 2751–61.
    Direct Link:
  • 20
    Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS/PAS-II). J Rheumatol 2005; 32: 2410–5.
  • 21
    Wolfe F, Rasker JJ, Boers M, Wells GA, Michaud K. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis Rheum 2007; 57: 935–42.
    Direct Link:
  • 22
    Robins JM, Gail MH, Lubin JH. More on “biased selection of controls for case-control analyses of cohort studies.” Biometrics 1986; 42: 293–9.
  • 23
    Del Rincon ID, Freeman GL, Haas RW, O'Leary DH, Escalante A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005; 52: 3413–23.
    Direct Link:
  • 24
    Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 1530–42.
    Direct Link:
  • 25
    Larsen A, Thoen J. Hand radiography of 200 patients with rheumatoid arthritis repeated after an interval of one year. Scand J Rheumatol 1987; 16: 395–401.
  • 26
    Kumeda Y, Inaba M, Goto H, Nagata M, Henmi Y, Furumitsu Y, et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46: 1489–97.
    Direct Link:
  • 27
    Davis JM III, Maradit-Kremers H, Gabriel SE. Use of low-dose glucocorticoids and the risk of cardiovascular morbidity and mortality in rheumatoid arthritis: what is the true direction of effect? J Rheumatol 2005; 32: 1856–62.
  • 28
    Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141: 764–70.
  • 29
    Huiart L, Ernst P, Ranouil X, Suissa S. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J 2005; 25: 634–9.
  • 30
    Huiart L, Ernst P, Ranouil X, Suissa S. Oral corticosteroid use and the risk of acute myocardial infarction in chronic obstructive pulmonary disease. Can Respir J 2006; 13: 134–8.
  • 31
    Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000; 43: 1801–8.
    Direct Link:
  • 32
    Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, de Faire U, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887–93.
  • 33
    Del Rincon ID, O'Leary DH, Haas RW, Escalante A. Effect of glucocorticoids on the arteries in rheumatoid arthritis [published erratum appears in Arthritis Rheum 2005;52:678]. Arthritis Rheum 2004; 50: 3813–22.
    Direct Link:
  • 34
    Caplan L, Wolfe F, Russell AS, Michaud K. Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol 2007; 34: 696–705.
  • 35
    Davis JM III, Maradit Kremers H, Crowson CS, Nicola PJ, Ballman KV, Therneau TM, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007; 56: 820–30.
    Direct Link:
  • 36
    Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med 2002; 17: 717–20.
    Direct Link:
  • 37
    Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994; 154: 97–101.
  • 38
    Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005; 142: 157–64.
  • 39
    Avorn J. In defense of pharmacoepidemiology: embracing the yin and yang of drug research. N Engl J Med 2007; 357: 2219–21.
  • 40
    Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: a retrospective cohort study from disease onset. J Rheumatol 1999; 26: 2562–71.
View Full Article (HTML) Get PDF (101K)